News & Media

Newsroom

SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741

12.2.2019

FDA Approves XCOPRI® (cenobamate tablets) CV, an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.

11.21.2019

Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology

11.13.2019

New National Epilepsy Survey Reveals Significant Disconnects on Important Issues Among Patients, Caregivers and Healthcare Professionals

11.1.2019

SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers

7.17.2019

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top